文献速递抗菌药物管理药物不良反应与药物警戒

头孢唑林与抗葡萄球菌青霉素治疗MSSA菌血症的比较综述

β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
PubMed 文献 · Pharmacotherapy · 2017-02-07

本综述比较头孢唑林与抗葡萄球菌青霉素(ASPs)治疗甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症的疗效与安全性。传统上ASPs为首选,头孢唑林因顾虑A型β-内酰胺酶水解及缺乏对照数据未作一线推荐。近期研究提示头孢唑林疗效相似且耐受性更好,因不良反应停药率更低,充分源控制与积极给药方案可能减轻接种物效应。

要点

  • 头孢唑林与ASPs治疗MSSA菌血症临床疗效相似,耐受性更好。
  • 头孢唑林因不良反应停药率低于ASPs。
  • 充分源控制和积极给药可能减轻头孢唑林接种物效应。

核心结论

  • 头孢唑林与ASPs治疗MSSA菌血症临床疗效相似,且耐受性更好、因不良反应停药率更低。

研究设计与样本

  • 本文为比较综述,聚焦头孢唑林与ASPs治疗MSSA菌血症的临床疗效与安全性。

主要发现

  • 近期临床研究提示头孢唑林与ASPs临床疗效相似。
  • 头孢唑林因药物不良反应停药率低于ASPs。
  • 充分源控制(如移除血管内导管、清创或引流)与积极头孢唑林给药可能减轻接种物效应并改善结局。

关键数值与推荐

  • 传统上ASPs为MSSA菌血症首选,万古霉素仅推荐用于严重青霉素过敏患者。
  • 头孢唑林可用于非严重青霉素过敏患者,但既往因A型β-内酰胺酶水解顾虑、不必要的革兰阴性覆盖选择压力及缺乏对照数据未作一线推荐。

临床怎么用

  • 对非严重青霉素过敏的MSSA菌血症患者,头孢唑林可作为ASPs的替代选择。
  • 使用头孢唑林时应确保充分源控制并考虑积极给药方案以减轻接种物效应。

局限性

  • 缺乏头孢唑林与ASPs治疗MSSA菌血症的大规模对照临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is associated with high morbidity and mortality. Traditionally, antistaphylococcal penicillins (ASPs) have been considered the agents of choice for the treatment of MSSA bacteremia. Vancomycin has been demonstrated to have poorer outcomes in several studies and is only recommended for patients with severe penicillin allergies. Although cefazolin is considered as an alternative to the ASPs for patients with nonsevere penicillin allergies, cefazolin offers several pharmacologic advantages over ASPs, such as more convenient dosing regimens, and antimicrobial stewardship programs are increasingly using cefazolin as the preferential agent for MSSA infections as part of cost-saving initiatives. Concerns about susceptibility to hydrolysis by type A β-lactamases, particularly at high inocula seen in deep-seated infections such as endocarditis; selective pressures from unnecessary gram-negative coverage; and lack of comparative clinical data have precluded recommending cefazolin as a first-line therapy for MSSA bacteremia. Recent clinical studies, however, have suggested similar clinical efficacy but better tolerability, with lower rates of discontinuation due to adverse drug reactions, of cefazolin compared with ASPs. Other variables, such as adequate source control (e.g., intravascular catheter removal, debridement, or drainage) and enhanced pharmacodynamics through aggressive cefazolin dosing, may mitigate the role of cefazolin inoculum effect and factor into determining improved clinical outcomes. In this review, we highlight the utility of cefazolin versus ASPs in the treatment of MSSA bacteremia with a focus on clinical efficacy and safety.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Li J, Echevarria KL, Traugott KA, et al. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins. Pharmacotherapy. 2017. PMID: 28035690. doi:10.1002/phar.1892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。